SC 13G: Boundless Bio, Inc.

AI Summary

SC 13G filing by Boundless Bio, Inc..

Risk Assessment

Risk Level: low

FAQ

Key Financial Figures

• $0.0001 — me of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti

Filing Documents

• tm2411383d1_sc13g.htm (SC 13G) — 75KB
• 0001104659-24-045227.txt ( ) — 76KB

(a) Name of Issuer

Item 1(a) Name of Issuer Boundless Bio, Inc. (the “ Issuer ”)

(b) Address of Issuer’s Principal Executive Offices

Item 1(b) Address of Issuer’s Principal Executive Offices 9880 Campus Point Drive, Suite 120, San Diego, California 92121

(a) Name of Person Filing

Item 2(a) Name of Person Filing This Schedule 13G is being jointly filed by Bayer HealthCare LLC (“ BHC ”), Bayer US Holding LP (“ BUSH LP ”), Bayer World Investments B.V. (“ BWI ”) and Bayer Aktiengesellschaft (“ Bayer AG ”) (collectively, the “ Reporting Persons ”).

(b) Address of Principal Business Office, or if none, Residence

Item 2(b) Address of Principal Business Office, or if none, Residence The business address for BHC and BUSH LP is 100 Bayer Boulevard, Whippany, New Jersey 07981. The business address for BWI is Siriusdreef 36, 2132 WT Hoofddorp, The Netherlands. The business address for Bayer AG is Kaiser-Wilhelm-Allee 1, 51368 Leverkusen, Germany.

(c) Citizenship

Item 2(c) Citizenship The Reporting Persons are citizens of: BHC – Delaware BUSH LP – Delaware BWI — The Netherlands Bayer AG — Germany

(d) Title of Class of Securities

Item 2(d) Title of Class of Securities Common Stock, par value $0.0001 per share (“ Common Stock ”)

(e) CUSIP Number

Item 2(e) CUSIP Number 10170A100

Filing pursuant to Rules 13d-1(b) or 13d-2(b) or (c)

Item 3. Filing pursuant to Rules 13d-1(b) or 13d-2(b) or (c) Not Applicable

Ownership

Item 4. Ownership (a) BHC is the direct beneficial owner of an aggregate of 1,615,201 shares of the Issuer’s Common Stock, which represents 7.3% of the Issuer’s Common Stock outstanding, based upon 22,239,333 shares of the Issuer’s Common Stock outstanding following the closing of the Issuer’s initial public offering (and assuming no exercise of the underwriters’ over-allotment option) as disclosed in the Issuer’s Final Prospectus. CUSIP No. 10170A100 Page 7 of 11 Pages BHC is controlled by BUSH LP. BWI is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer AG. Accordingly, Bayer AG may be deemed to be an indirect beneficial (b) Percent of class: BHC – 7.3% BUSH LP – 7.3% BWI — 7.3% Bayer AG — 7.3% (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: BHC — 1,615,201 BUSH LP — 1,615,201 BWI — 1,615,201 Bayer AG — 1,615,201 (iii) Sole power to dispose or to direct the disposition of: 0 (iv) Shared power to dispose or to direct the disposition of: BHC — 1,615,201 BUSH LP — 1,615,201 BWI — 1,615,201 Bayer AG — 1,615,201

Ownership

Item 5. Ownership of Five Percent or Less of a Class Not Applicable

Ownership of More than Five Percent on Behalf of Another Person

Item 6. Ownership of More than Five Percent on Behalf of Another Person Not Applicable Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company Not Applicable CUSIP No. 10170A100 Page 8 of 11 Pages

Identification and Classification of Members of the Group

Item 8. Identification and Classification of Members of the Group Not Applicable

Notice of

Item 9. Notice of Dissolution of Group Not Applicable

Certification

Item 10. Certification By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11. CUSIP No. 10170A100 Page 9 of 11 Pages

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. Date: April 9, 2024 BAYER HEALTHCARE LLC By: /s/ Priyal Patel Priyal Patel, Treasurer BAYER US HOLDING LP By: /s/ Priyal Patel Priyal Patel, Treasurer BAYER WORLD INVESTMENTS B.V. By: /s/ Kati Schnuerer Kati Schnuerer, Managing Director BAYER AKTIENGESELLSCHAFT By: /s/ Thomas Hoffmann Thomas Hoffmann, Head of Treasury CUSIP No. 10170A100 Page 10 of 11 Pages EXHIBIT INDEX A. Joint Filing Agreement, dated April 9, 2024, by and between Bayer HealthCare LLC, Bayer US Holding LP, Bayer World Investments B.V. and Bayer Aktiengesellschaft. CUSIP No. 10170A100 Page 11 of 11 Pages EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree to jointly prepare and file with the United States Securities and Exchange Commission this Schedule 13G and any future amendments hereto (including amendments on Schedule 13D or Schedule 13G, as applicable) reporting each of the undersigned’s affirm that such Schedule 13G is being filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other, except to the extent that it knows or has reason to believe that such information is inaccurate. Date: April 9, 2024 BAYER HEALTHCARE LLC By: /s/ Priyal Patel Priyal Patel, Treasurer BAYER US HOLDING LP By: /s/ Priyal Patel Priyal Patel, Treasurer BAYER WORLD INVESTMENTS B.V. By: /s/ Kati Schn

View Full Filing

View this SC 13G filing on SEC EDGAR